Sector
PharmaceuticalsOpen
₹5,812Prev. Close
₹5,844.6Turnover(Lac.)
₹566.34Day's High
₹5,913.5Day's Low
₹5,76552 Week's High
₹10,524.9552 Week's Low
₹4,902Book Value
₹620.51Face Value
₹10Mkt Cap (₹ Cr.)
13,577.8P/E
37.1EPS
157.36Divi. Yield
223 Feb 2024
12:00 AM
AGM
Announcement Date: 23 Feb, 2024
23 Feb 2024
12:00 AM
Dividend
Dividend Amount: 117
Record Date: 03 May, 2024
13 Nov 2023
12:00 AM
EGM
22 Mar 2024
12:00 AM
BookCloser
18 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
The board has proposed a final dividend of ₹117 per equity share (face value of ₹10), subject to shareholders approval at the next Annual General Meeting.
| Y/e 31 Mar( In .Cr) | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|
Equity Capital | 23 | 23 | 23 | 23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 992.5 | 1,252.8 | 2,202.6 | 2,096 |
Net Worth | 1,015.5 | 1,275.8 | 2,225.6 | 2,119 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
|---|---|---|---|---|
Revenue | 2,956.6 | 3,070.6 | 2,770.8 | 2,463.6 |
yoy growth (%) | -3.71 | 10.81 | 12.46 | 4.08 |
Raw materials | -1,306.8 | -1,347.4 | -1,145.9 | -1,004.1 |
As % of sales | 44.19 | 43.88 | 41.35 | 40.75 |
Employee costs | -433.9 | -449.7 | -406.8 | -368.5 |
| Y/e 31 Mar( In .Cr) | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
|---|---|---|---|---|
Profit before tax | 768.4 | 659.2 | 609.8 | 514.6 |
Depreciation | -66.7 | -99.9 | -102.7 | -102.2 |
Tax paid | -313.2 | -185.7 | -229.2 | -188.6 |
Working capital | -30.59 | 457.2 | 126.6 | -231.1 |
Other operating items |
| Y/e 31 Mar | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -3.71 | 10.81 | 12.46 | 4.08 |
Op profit growth | 14.6 | 6.7 | 16.06 | 0.39 |
EBIT growth | 16.78 | 8.02 | 18.38 | 6.83 |
Net profit growth | 128 | 8.82 | 16.74 | 7.16 |
| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2004 | Dec-2003 |
|---|---|---|---|---|
Gross Sales | 2,013.2 | 1,996.1 | 794.09 | 707.2 |
Excise Duty | 0 | 0 | 55.7 | 49.9 |
Net Sales | 2,013.2 | 1,996.1 | 738.4 | 657.29 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 116.1 | 317.3 | 26.6 | 21.29 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Aditya Narayan
Independent Director
Usha Thorat
Non Executive Director
Vaibhav KARANDIKAR
Independent Director
Rahul Bhatnagar
Managing Director
Rodolfo Hrosz
Company Sec. & Compli. Officer
Radhika Shah
Whole Time Director
Renee Amonkar
Whole Time Director & CFO
Rachid Ayari
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sanofi India Ltd
Summary
Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India. Sanofi, one of the worlds leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital. During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine Rabipur. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 1999-2000, Aventis launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H. In the year 2001, Rhone-Poulenc Rorer
Read More
What is the Sanofi India Ltd share price today?
The Sanofi India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹5895.7 today.
What is the Market Cap of Sanofi India Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi India Ltd is ₹13577.80 Cr. as of 02 Apr ‘25
What is the PE and PB ratio of Sanofi India Ltd?
The PE and PB ratios of Sanofi India Ltd is 37.1 and 15.62 as of 02 Apr ‘25
What is the 52 Week High and Low of Sanofi India Ltd?
The 52-week high/low is the highest and lowest price at which a Sanofi India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sanofi India Ltd is ₹4902 and ₹10524.95 as of 02 Apr ‘25
What is the CAGR of Sanofi India Ltd?
Sanofi India Ltd's CAGR for 5 Years at -1.98%, 3 Years at -7.80%, 1 Year at -27.92%, 6 Month at -17.80%, 3 Month at -3.98% and 1 Month at 14.44%.
What is the shareholding pattern of Sanofi India Ltd?
The shareholding pattern of Sanofi India Ltd is as follows:
Promoters - 60.40 %
Institutions - 28.57 %
Public - 11.04 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
